Date: 2013-07-18
Type of information: Series A financing round
Company: Audentes Therapeutics (USA - CA)
Investors:
Amount: $30 million
Funding type: series A financing round
Planned used: This funding creates a global biotechnology company dedicated to the development of treatments for rare muscle diseases using gene therapy technology. Audentes, headquartered in San Francisco, CA, was founded by Mr. Patterson in November, 2012 in collaboration with Thomas J. Schuetz, M.D., Ph.D. and OrbiMed Advisors. The Audentes Board of Directors will consist of Jonathan Silverstein (OrbiMed Advisors), who will serve as Chairman, Kush Parmar, M.D., Ph.D. (5AM Ventures), Thomas Woiwode, Ph.D. (Versant Ventures), Dr. Schuetz, who will act as an independent director, and Mr. Patterson. This funding will allow the Company to further advance its two lead programs based on adeno-associated virus (AAV) gene therapy technology, AT001 for X-linked Myotubular Myopathy (XLMTM) and AT002 for Pompe disease, and to evaluate additional candidate programs.
Others: * On July 18, 2013, Audentes Therapeutics, a recently founded biotechnology company dedicated to the development of innovative treatments for rare muscle diseases, announced the closing of a $30 million Series A financing. The financing was led by OrbiMed Advisors with the participation of 5AM Ventures and Versant Ventures.
Therapeutic area: Rare diseases - Genetic diseases
